Agilon Health’s first quarter saw a marked positive reaction from the market, reflecting a combination of operational progress and strategic focus on profitability. Management credited the quarter’s performance to enhanced data capabilities, disciplined payer contracting, and improved physician engagement. Executive Chairman Ronald Williams emphasized that “operational discipline, the strength of our long-term physician partnerships, and early benefits from the strategic decisions we made last year” were key contributors. Advancements in early disease detection and the scaling of heart failure programs also helped manage medical costs, supporting better-than-expected results.
Is now the time to buy AGL? Find out in our full research report (it’s free for active Edge members).
agilon health (AGL) Q1 CY2026 Highlights:
- Revenue: $1.42 billion vs analyst estimates of $1.38 billion (7.3% year-on-year decline, 3.2% beat)
- Adjusted EPS: $2.32 vs analyst estimates of $0.93 (significant beat)
- Adjusted EBITDA: $53.84 million vs analyst estimates of $36.98 million (3.8% margin, 45.6% beat)
- The company lifted its revenue guidance for the full year to $5.74 billion at the midpoint from $5.50 billion, a 4.5% increase
- EBITDA guidance for the full year is $25 million at the midpoint, above analyst estimates of -$16.21 million
- Operating Margin: 0.3%, up from -1.4% in the same quarter last year
- Customers: 426,000, down from 511,000 in the previous quarter
- Market Capitalization: $1.16 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From agilon health’s Q1 Earnings Call
- Jailendra Singh (Truist Securities) asked why ACO REACH EBITDA guidance remained unchanged despite strong Q1 results. CFO Jeffrey Alan Schwaneke clarified the Q1 benefit was tied to 2025 adjustments, with future upside dependent on further claims development.
- Matthew Dineen Shea (Needham) inquired about the timeline for clinical program rollout and when COPD and dementia initiatives would impact financials. Schwaneke said benefits could appear in 2026, but results depend on claims data maturation.
- Analyst (Deutsche Bank) questioned whether improved 2026 guidance sets a higher base for 2027. Schwaneke emphasized the current results provide a solid foundation for continued margin improvement into future contracting cycles.
- Luismario Higuera (Citigroup) sought clarity on the drivers of medical cost trends and the impact of new geography entry expenses. Schwaneke explained ongoing cost pressures are concentrated in Part B and inpatient costs, with geo-entry expenses tracking expectations.
- Ryan Daniels (William Blair) asked when agilon would pursue growth in member base and new markets. Executive Chairman Ronald Williams confirmed the current focus is on in-market growth and operational execution, with broader expansion to be considered in the future.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely monitor (1) the adoption and measured outcomes of new clinical pathways for COPD and dementia, (2) the continued impact of enhanced data integration on risk adjustment and cost management, and (3) the results of payer contract renewals, especially as the company prepares for 2027 regulatory changes. Execution in these areas will be central to tracking agilon health’s ability to sustain profitability and quality improvements.
agilon health currently trades at $69.12, up from $27.85 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
